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carcinoma elicited multi-dysfunction along PTX
and chronic kidney disease with microcytic
anemia
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Background: The hypothalamic–pituitary (h-p) unit is a particularly radiosensitive region in the central nervous
system. As a consequence, radiation-induced irreversible, progressively chronic onset hypopituitarism (RIH)
commonly develops after radiation treatments and can result in variably impaired pituitary function, which is
frequently associated with increased morbidity and mortality.
Case presentation: A 38-year-old male subject, previously having received radiotherapy for treatment of nasopharygeal
carcinoma (NPCA) 16 years ago, appeared at OPD complaining about his failure in penile erection, loss of pubic hair,
atrophy of external genitalia: testicles reduced to 2×1.5 cm; penile size shrunk to only 4 cm long. Characteristically, he
showed extremely lowered human growth hormone, (HGH, 0.115 ng/mL), testosterone (<0.1 ng/mL), total thyroxine
(tT4: 4.740 g/mL), free T4 (fT4, 0.410 ng/mL), cortisol (2.34 g/dL); lowered LH (1.37 mIU/mL) and estradiol (22 pg/mL);
highly elevated TSH (7.12 IU/mL). As contrast, he had low end normal ACTH, FSH, total T3, free T3, and estriol; high end
normal prolactin (11.71 ng/mL), distinctly implicating hypopituitarism-induced hypothyroidism and hypogonadism.
serologically, he showed severely lowered Hb (10.6 g/dL), HCT (32.7%), MCV (77.6 fL), MCH (25.3 pg), MCHC (32.6 g/dL),
and platelet count (139×103/L) with extraordinarily elevated RDW (18.2%), together with severely lowered ferritin
(23.6 ng/mL) and serum iron levels; highly elevated total iron binding capacity (TIBC, 509 g/dL) and transferrin
(363.4 mg/dL), suggesting microcytic anemia. Severely reduced estimated glomerular filtration rate (e-GFR)
(89 mL/mim/1.73 m2) pointed to CKD2. Hypocortisolemia with hyponatremia indicated secondary adrenal insufficiency.
Replacement therapy using androgen, cortisol, and Ringer’s solution has shown beneficial in improving life quality.
Conclusions: To our believe, we are the first group who report such complicate PTX dysfunction with adrenal cortisol
insufficiency concomitantly occurring in a single patient.
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The hypothalamic–pituitary (h-p) unit is a particularly
radiosensitive region of the central nervous system. As a
consequence, radiation-induced hypopituitarism (RIH)
commonly develops after radiation treatments [1,2]. RIH, an
irreversible and progressive chronic onset disorder, can result
in a variable impairment of pituitary function [1,2], usually
associated with increased morbidity and mortality [3].
Selective radiosensitivity of the neuroendocrine axes,
with the human growth hormone (HGH) axis being the
most vulnerable, accounts for the high frequency of
HGH deficiency (GHD) following irradiation of the h–p
axis with doses less than 30 Gy [2]. Life table analysis
shows that the percent damages are dose- and time-
dependent, and the frequency of GHD can substantially
increase to reach as high as 50–100% [3]. At average, to
lose 75% of the normal axis function of GHD may take
3.3 years, for LH/FSH, 7.8 years; and ACTH, 8.2 years
[4]. Abnormalities in gonadotrophin secretion occurs
dose-dependently but infrequently, and hyperprolactine-
mia is usually subclinical [2].
Thyroid hormones, directly or indirectly through erythro-
poietin, stimulate growth of erythroid colonies. Anemia is
often the first sign of hypothyroidism diagnosed in 20-
60% patients with hypothyroidism [5]. Numerous mecha-
nisms are involved in the pathogenesis of these anemias
which can be microcytic, macrocytic and normocytic [6].
Microcytic anemia is usually ascribed to malabsorption
and failure in transport of iron. Macrocytosis is found in
up to 55% patients with hypothyroidism and may result
from the insufficiency of the thyroid hormones themselves
without nutritive [5] like vitamin B12 and folic acid, and is
frequently seen in pernicious anemia. Normocytic anemiaA
Figure 1 Appearance of this genital organ-penis. Shrunken penis is app
treating nasopharyngeal carcinoma (NPCA) 16 years ago. (A: Penis regularlyis characterized by reticulopenia, hypoplasia of erythroid
lineage, and decreased level of erythropoietin and mainly
is associated with regular erythrocyte survival [6]. Worth
note, pernicious anemia occurs 20 times more frequently
in patients with hypothyroidism than generally [5].
We report a male patient who showed apparently
shrunken penis and reduced testicular size, erectile dys-
function and loss of libido 16 years post radiotherapy of
his nasopharyngeal carcinoma (NPCA).
Case presentation
A 38 years old male patient visited the Urological Out-
patient Department and complained mainly about
complete loss of penile erection already for half a year.
The fact was soon recognized that he had been diag-
nosed to be with NPC, epidermoid carcinoma, nonker-
atinizing in July 2, 1997, Stage cT3N2bM0 (previous
AJCC staging system, 4th edition, not AJCC 7th staging
system). The overall cumulative radiotherapy dose was
7140 cGy/42 fractions. The fraction dose was 170 cGy.
The irradiation was delivered with conventional 2-
dimensional radiotherapy using the linear accelerator
equipped with 6 MV energy. Complete tumor response
was achieved. The physical examination revealed shrunken
external genitalia with penile size severely reduced to only
4 cm long accompanied with complete loss of pubic hair
(Figure 1). His testicles are apparently with atrophy, size
severely reduced to approximately 2×1.5 cm (not shown).
Tracing back to the past history, the patient was diag-
nosed with nasopharyngeal carcinoma (NPCA) and as in
the above mentioned he had received cumulative radio-
therapy dose 7140 cGy/42 fractions (170 cGy/per fraction)
sixteen years ago and didn’t receive any extra surgery orB
arently with size reduced to only 4 cm long post radiotherapy for
appearing, B: Measuring size of penis)(patient: male, age 38).
Lin et al. BMC Urology 2014, 14:19 Page 3 of 8
http://www.biomedcentral.com/1471-2490/14/19chemotherapy for this NPCA. The NPCA was successfully
treated and didn’t recur up to present. In the same dur-
ation, he successfully went on to father three healthy chil-
dren, age 16, 15 and 10 respectively.
The sagittal views reveal his hypophysis has been injured
severely. The nasal pharyngeal area is severely deformed.
(Figure 2). After testis biopsy, the pathological report
showed pictures of mature testis with spermatogenesis,
well developed seminiferous tubules and Leydig cells, yet
the number of mature spermatozoa is fair per cross sec-
tion of seminiferous tubules. The thickening of tubular
wall indicates early stage testicular atrophy (Figure 3).
The laboratory data revealed extremely lowered HGH,
lower levels of LH, testosterone, E2, total thyroxine and
free T4, accompanied with severely lowered cortisol, low
end level ACTH, FSH, total T3, and free T3; highly ele-
vated TSH, high end normal prolactin, and normalA. Sagittal view B
C. Sagittal view D
Figure 2 MRI scanogram of patient Lu’s brain. The sagittal views (pictu
pharyngeal area is severely deformed.estriol were also noticed (Table 1). Complete blood
count revealed low RBC, severely lowered Hb, HCT,
MCV, MCH, MCHC, PLT, MPV, elevated RDW (Table 2);
severely lowered ferritin, low serum iron levels, highly ele-
vated serum total iron binding capacity, elevated transfer-
rin and the low end marginal e-GFR (Table 3). This
patient was commenced on replacement therapy with cor-
tisone injections, Ringer’s solution (3%), thyroxine (T4),
and testosterone replacement were immediately
prescribed.
Discussion
Concomitant occurrence of low end normal ACTH,
extremely lowered HGH, and highly elevated TSH
level with significantly lowered tT4 and fT4 (Table 1)
implicated the second stage hypothyroidism (Figure 4).
Buchanan et al. indicated that hypothyroidism also can. Sagittal view
. Sagittal view
res A-D) reveal the hypophysis has been injured severely and the nasal
A B
C D
Figure 3 Hematoxylin-Eosin stain of testicualr tissues. A: 100×; B: 200×; C: 300×; and D: 400× (date: December 20, 2012). The thickening of
seminiferous tubular walls is a typical symptom of early testicular atrophy. The Leydig cells and Sertoli cells appear normal with mature
spermatogenesis, however with reduced density and lack of compact cell linings as usually seen in normal subjects.
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ever such a manifestation did not occur in this male
victim (Table 1).
The HE stain of the patient’s seminiferous tubule re-
vealed normal maturation of spermatozoa, but much less
in population, implying infertility (Figure 3). Diminished
secretion of LH can result in hypogonadism [8] (refer to
Table 1 and Figure 4).
Secondary hypocortisolemia associated with hypona-
tremia (Table 3, Figure 4) occurred because of lacking
adrenocorticotropin that is responsible for triggering the
adrenal gland to produce the adrenal cortisol [9,10].
An e-GFR 89 mL/min/1.73 m2 implied stage 2 chronic
kidney disease (CKD2) (Table 3). Hypocortisolemia (Table 1)
can cause reduced e-GFR.
This patient was affiliated with microcytic anemia as
evidenced by hypothyroidism (Table 1), low Hb, MCV(Table 2) and severely lowered ferritin (Table 3). Pituit-
ary gland has an influence on erythropoiesis. Anaemia is
thought to be due to loss of thyrotrophic and adreno-
trophic hormones [11]. Testosterone enhances erythro-
poiesis by increasing renal erythropoietin production
[11-13]. Severely lowered ferritin (Table 3) implies poor
iron absorption by the duodenal lumen (Figure 5) [14].
This patient was commenced on replacement therapy
with cortisone injection, Ringer’s solution (3%), thyrox-
ine (T4), and testosterone replacement were immediately
prescribed. Muscle strength was rapidly restored after
replacement. Unlike primary hypogonadism, secondary
hypogonadism often has a cause that is amenable to spe-
cific treatment. For that reason, finding the cause carries
particular importance [18]. If the hypogonadism occurred
postpubertally, usually only LH need to be replaced.
In hypogonadism secondary to hypothalamic disease,
Table 1 Endocrine analysis
Hormone Value Normal range Comment
ACTH, pg/mL 12.2 9.0–52.0 (website 1) Low end normal
GH, ng/mL 0.115 1.000–9.000 (website 2) Severely lower
Prolactin, ng/mL (EIA) 11.71 male: 2.64–13.13; 4–23 (website 3); (3–15, website 4) High end normal
FSH, mIU/mL (EIA/LIA) 4.91 males: 1.27–19.26; 1.4–18.1 (male) (website 5) Low end normal
LH, mIU/mL 1.37 males: 1.50–9.30 (website 5) Lower
Estradiol, E2 (EIA/LIA), pg/mL 22 males: 25–70 (website: 4) Lower
Estriol (E3) (EIA), pg/mL <0.017 0–3 (website: 6) Normal
Testosterone (EIA/LIA), ng/mL <0.1 Blood: 3.0–12.0 (website 5) Trace only
T4 total (biochem), μg/dL 4.740 6.09–12.23 Extremely lower
Free T4 (EIA/LIA), ng/dL 0.41 0.54–1.40 Extremely lower
T3 total, (EIA/LIA), ng/dL 92.88 87.00–178.00 Low end normal
Free T3 (EIA/LIA), pg/mL 2.780 2.500–3.900; 2.300–6.190 (website 7) Low end normal
TSH (EIA/LIA), μIU/mL 7.12 0.34–5.60 Highly elevated
Cortisol, μg/dL - - -
At 8 am 2.34 6.7–22.6 Severely lowered;
At 16 pm 3.74 0–10 Low end
Websites: 1. http://www.nlm.nih.gov/medlineplus/ency/article/003695.htm.
2. Medline Plus. 3. Selleckchem.com. 4-30 ng/ml in females and 4-23 ng/mL in males. 4. MedHelp. 5. Health Board. 6. High-Pro.com. 7. Men’s Health Message
Board. 7. About.Com. Thyroid disease. Practice Notebook. Updated July 31, 2003; by Kenneth N. Woliner, M.D., A.B.F.P. Website: Nova
Tech ImmunodiagnosticaGmbH.
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ministration of GnRH. Testosterone can be replaced
whether the hypogonadism is primary or secondary. Un-
like estrogen, testosterone itself is not suitable for oral re-
placement, because it is catabolized rapidly during its first
pass through the liver. Derivatives of testosterone that are
alkylated in the 17α position do not undergo this rapid
hepatic catabolism; however, these agents appear to lackTable 2 Complete blood count*
Value obtained Normal range Comment
WBC, 103/μL 5.2 3.5–9.6 Normal
RBC, 106/μL 4.21 4.20–6.23 Low end margin
Hb, g/dL 10.6 13–18 Severely lower
HCT, % 32.7 38.8–53.1 Severely lower
MCV, fL 77.6 80.0–100.0 Severely lower
MCH, pg 25.3 27.0–32.0 Severely lower
MCHC, g/dL 32.6 33.3–36.0 Lower
PLT, 103/μL 139 150–450 Severely lower
PDW, % 17.6 15.5–18.0 Normal
MPV, fL 6.6 6.8–13.5 Lower
RDW, % 18.2 12.1–15.2 Highly elevated
*WBC: white blood cells. RBC: red blood cells. Hb: hemoglobin. HCT:
hematocrit. MCV: mean corpusular volume. MCH: mean corpusulr hemoglobin.
MCHC: mean corpusular hemoglobin concentration. PLT: platelet count. PDW:
platelet distribution width. MPV: mean platelet volume. RDW: red blood cell
distribution width.the full virilizing effect of testosterone, and they may
cause hepatic toxicity, including cholestatic jaundice, a
cystic condition of the liver called peliosis, and, possibly,
hepatocellular carcinoma. Consequently, the 17α-
alkylated androgens should not be used to treat testos-
terone deficiency [18].
During replacement therapy, clinicians should monitor
patients for the efficacy and side effects of testosterone.
Serum testosterone concentrations can vary with any of
these preparations, so testosterone should be measured
more than once to determine whether the initial dose is
optimal. Serum testosterone should be measured again
after a dose is changed and then once or twice a year. If
the serum testosterone concentration is maintained within
the normal range, the patient should experience reversal
of the consequences of testosterone deficiency. Specific-
ally, energy, libido, hemoglobin concentration, muscle
mass, and bone density will increase [18]. Noteworthy,
hypogonadism has been associated with several risk fac-
tors of atherosclerosis including obesity, Type II DM,
dyslipidemia and hypertension.
Hypogonadism having low testosterone levels with in-
creased carotid intima-media thickness (IMT) may evi-
dence early atherosclerosis. In addition, low testosterone
increases the susceptibility to myocardial ischemia. Erect-
ile dysfunction is a symptom of hypogonadism, but also
an end result of atherosclerosis and a predictor of coron-
ary artery atherosclerosis (CAD) [19].
Table 3 Biochemical tests of serum
Parameters Value obtained Normal range Comment
Serum BUN, mg/dL 16 8–20 Normal
s-GOT (AST), IU/L 28 15–41 Normal
s-GPT (ALT), IU/L 14 10–40 Normal
TIBC, μg/dL 509 255–450 Highly elevated
Ferritin (EIA), ng/mL 23.6 30.0–336.2 Severely lower
Transferrin (Nephelometry), mg/dL 363.4 180–329 Highly elevated
Serum Iron (Fe), μg/dL 55 Adult male: 45–182 Lower margin
Creatinine (bood), mg/dL 0.95 0.70–1.20 Normal
e-GFR, mL/min/1.73 m2 89 90–120 Low end margin
Na+, mEq/L or mmol/L 124 135–146 Severely lower
Cu2+ (blood), μg/dL 129.75 70-140 Normal
TIBC: Total iron binding capacity. e-GFR: estimated glomerular filtration rate.
s-GOT: serum glutamate-oxaloacetate transaminase. s-GPT: serum glutamate-pyruvate transaminase.
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with rise in haemoglobin to 12.3 g/dL after 3 months and
13.5 g/dL, MCV 86 after 7 months. It is important to re-
member the role of pituitary hormones in erythropoiesis
and consider hypopituitarism in the differential diagnosis
of iron deficiency anaemia. Steroid and testosteroneFigure 4 Schematic presentation indicating the pathological prevalen
nasopharyngeal carcinoma (NPCA) 16 years ago (patient: male, age 3replacement corrected anaemia in this patient however it
is not clear which hormone played a major role.
Hypopituitarism associated secondary adrenal insuf-
ficiency must be frequently noted to avoid the occur-
rence of severe hyponatremia. Replacement therapy
with testosterone, thyroid hormone, coritsol and salinece occurring in this male patient post radiotherapy for treating
8).
Figure 5 The highly elevated serum transferrin due to lack of effective formation of ferric ion-carbonate-transferrin complex. The
dissociation constant of this complex is Kd =10-22 [15]. Iron is absorbed from the duodenal lumen t by divalent-metal transporter 1 (DMT1) after
reduced by the cytochrome b, Cyt-b. Intracellular iron enters the labile iron pool (LIP), either exported by iron-regulated protein 1 (IREG1) and
then oxidized by hephaestin or, stored in ferritin cores [14] up to 1000 mg Fe. In the presence of bicarbonate ions supplied from anhydrase I,
transferrin (Tf) and Fe3+ ions form a ternary complex ‘transferrin-bicarbonate-ferric ion complex’ to facilitate transport of ferric ions to be incorpo-
rated into hemoglobin [16,17]. A complex of transferrin receptor 1 (TfR1), the hemochromatosis protein (HFE) and β2-microglobulin, is supposed
to act as primarily the iron-biosensor [14].
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sodium loss through the small intestine of mammals.
Sodium depletion, however, does not affect cortisol
levels. So cortisol cannot be used to regulate serum so-
dium [20]. The original task of cortisol may have been
sodium transport [21].
Radiation-induced GHD may progressively and fre-
quently develop in the first 10 years after radiation deliv-
ery [22]. Radiation induced anterior pituitary hormone
deficiencies are irreversible and progressive; a recognized
complication of cranial irradiation in cancer survivors–
in particular, a very sensitivity and high incidence of GH
deficiency (GHD) is observed [2], some cases may reach
a prevalence of GHD between 50 and 100%. Replace-
ment not only could improve the life quality, but also
sustain the life expectancy.
Regular assessments of anterior-pituitary function are
imperative in such patients, to achieve a timely diagnosis
and to enable introduction of appropriate hormone-
replacement therapy [2,23,24]. To increase tumour-relatedsurvival rates, a long-term monitoring tailored to the in-
dividual risk profile is required to avoid the sequelae of
untreated pituitary hormonal deficiencies and resultant
decrease in the quality of life [1].
Conclusions
Damage resulting from radiotherapy is a progressive,
chronic, and irreversible process. This case has taken
16 years to elicit PTX axis and adrenal dysfunction and
concomitantly, secondary hypopituitarism complicated
with second stage hypothyroidism, microcytic anemia,
secondary hypocortisolemia with hyponatremia, sec-
ondary hypogonadism, and CKD2. Replacement therapy
using T4, testosterone, cortisol, and 3% Ringer’s solu-
tion infusion has shown rather beneficial to his life
quality.
To our believe, we are the first group who report such
a complicate PTX dysfunction which also involves ad-
renal cortisol insufficiency, chronic kidney disease and
microcytic anemia concomitantly in a single patient.
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